Relationship between haemoglobin [A.sub.1c] values and recurrent cardiac events: a retrospective, longitudinal cohort study

Objective: This study set out to analyse the impact of baseline glycosylated haemoglobin [A.sub.1c] ([HbA.sub.1c]) values on the incidence of recurrent cardiac events in patients prescribed optimal secondary prevention medications and receiving aggressive cardiac risk factor management. Methods: Thi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical drug investigation 2008-08, Vol.28 (8), p.501
Main Authors: Kauffman, Amy B, Delate, Thomas, Olson, Kari L, Cymbala, Alicia A, Hutka, Kara A, Kasten, Sheila L, Rasmussen, Jon R
Format: Article
Language:English
Subjects:
Cardiovascular diseases
Complications and side effects
Diabetes
Glycosylated hemoglobin
Measurement
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study set out to analyse the impact of baseline glycosylated haemoglobin [A.sub.1c] ([HbA.sub.1c]) values on the incidence of recurrent cardiac events in patients prescribed optimal secondary prevention medications and receiving aggressive cardiac risk factor management. Methods: This was a retrospective study conducted at Kaiser Permanente Colorado and included adults followed by a clinical pharmacy specialist-managed cardiac risk service (CPCRS) with an incident cardiac event and an [HbA.sub.1c] value measured within 1 year prior or 60 days after the incident cardiac event was identified. Cox proportional hazards models were constructed to assess the relationship between [HbA.sub.1c] levels and recurrent cardiac events (assessed as continuous and categorical measures) after adjustment for potential confounding variables. Results: Of 5663 patients identified within an incident cardiac event between January 1999 and March 2005, 1270 (22.4%) patients had a baseline [HbA.sub.1c] value recorded. Of these 1270 patients, 215 (16.9%) had a recurrent cardiac event. Compared with the 'no recurrent event' cohort, the 'recurrent event' cohort were younger, less likely to have undergone an initial coronary artery bypass graft, and more likely to have undergone percutaneous coronary intervention with or without stent. The recurrent event cohort was also less likely to have purchased an HMG-CoA reductase inhibitor ('statin') [p = 0.043] at the time of the incident cardiac event. There was no significant difference in mean baseline [HbA.sub.1c] value between the cohorts. There were also no significant differences between the cohorts when categorized by baseline [HbA.sub.1c]
ISSN:1173-2563